Bioorganic and Medicinal Chemistry Letters p. 1416 - 1419 (2017)
Update date:2022-08-11
Topics:
Ding, Zhongpeng
Cheng, Hejuan
Wang, Shixiao
Hou, Yingwei
Zhao, Jianchun
Guan, Huashi
Li, Wenbao
Plinabulin, a drug targeting microtubule of cancer cells, has been currently tried in its phase III clinical study. However, low efficacy caused by poor pharmacokinetic (PK) properties has been considered to be the main obstacle to approved by the Food and Drug Administration. Herein, we introduced a deuterium atom as an isostere in its structure to become a new compound named (MBRI-001, No. 9 in a series of deuterium-substituted compounds). The structure of MBRI-001 was characterized by HRMS, NMR, IR and a single crystal analysis. MBRI-001 exhibited better pharmacokinetic characteristics than that of plinabulin. Additionally, its antitumor activity is in a low nanomolar level for a variety of cancer cell lines and high activity against human NCI-H460 xenograted in mice intravenous administration. Importantly, continuous administration of MBRI-001 exhibited lower toxicity compared to docetaxel. We thus suggest that MBRI-001 could be developed as a promising anti-cancer agent in near future.
View MoreContact:86-311-83160559
Address:shijiazhuang
JiYi Chemical (Beijing) Co., Ltd.
Contact:+86-10-89385733
Address:Shilou Town of Fangshan District, Beijing
website:http://www.hope-chem.com
Contact:86-21-58090396-805
Address:Floor 4, Building 5, No.588 Tianxiong Road, Zhoupu International Medical Zone, ShangHai, China
Shandong Loyal Chemical industrial Co.,Ltd
Contact:0533-7451788
Address:Linzi Chemical Industrial Park, Zibo, Shandong Province
website:http://www.NEM.COM.CN
Contact:+86-393-4411771
Address:The west section of shengli Road,Puyang,Henan Province,China
Doi:10.1021/jacs.7b05073
(2017)Doi:10.1007/BF00568264
()Doi:10.1016/0022-328X(90)87002-U
(1990)Doi:10.1039/c2jm33735e
(2012)Doi:10.1016/S0022-1139(00)83362-X
(1985)Doi:10.1002/cctc.201601070
(2016)